Canopy Growth Corporation produces, distributes, and sells cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. It operates through two segments: Cannabis and Storz & Bickel. Its product range includes vaporizers and accessories, dried flower, pre-rolled joints, oils, vapes, beverages, extracts, concentrates, softgel capsules, and cannabis edibles such as gummies. The company also runs an e-commerce shop, a medical cannabis online distribution platform, and an online medical cannabis clinic. It sells under brands including Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Abba Medix, Storz & Bickel, Wana, Claybourne, Apollo, Canada House, R'belle, LowKey, MTL Cannabis, DeeLish, and DOJA. Formerly Tweed Marijuana Inc., it changed its name to Canopy Growth Corporation in September 2015 and is headquartered in Smiths Falls, Canada.
Canopy Growth Seeks Another Reverse Stock Split as Shares Fall Below $1
Canopy Growth is asking shareholders to approve another reverse stock split, with a vote scheduled for Sept. 25, after its shares fell back below $1 per share. The cannabis company last executed a reverse split on Dec. 15, 2023, and its stock has since dropped roughly 80% from pre-reverse-split levels, including a nearly 50% decline before a brief marijuana stock rally. A $1 minimum share price is a key listing requirement on major exchanges, and Canopy Growth is proactively seeking the split to protect its listing. The company reported sales growth across all its divisions in the first quarter of fiscal 2027, with an overall top-line gain of 13%, while its loss was 68% lower than in the same quarter of the previous year. A reverse split is not a positive development and is typically a move a company makes when it has no better option, but shareholders likely have little choice but to approve the request, as voting it down would make it much harder for Canopy Growth to run its business.
CGC · Capital · Negative Canopy Growth is seeking another reverse stock split to protect its listing after shares fell below $1, a move the article calls a sign of having no better option.
Canopy Growth enters UK medical cannabis market with GROW Group supply deal
Canopy Growth Corporation announced an agreement to supply four Canadian-grown medical cannabis flower strains for distribution in the United Kingdom, marking the company's official market entry into the UK. Under the agreement, the Canadian-grown flower will be supplied to GROW Group U.K. Ltd., a distributor of prescribed cannabis-based medicines across Europe. GROW Group will commercialize and distribute the products across the UK under Canopy Growth's global Spectrum Therapeutics medical brand. The expansion builds on the recent renewal of European Union Good Manufacturing Practice certification at Canopy Growth's cultivation facility in Kincardine, Ontario, which enables the company to export medical cannabis across European markets.
CGC · Demand · Positive Canopy Growth signs a supply deal to enter the UK medical cannabis market, expanding end-customer distribution for its Spectrum Therapeutics products.
GROW Group U.K. Ltd. · Demand · Positive GROW Group gains a supply agreement to commercialize and distribute Canopy Growth's medical cannabis products across the UK.
Canopy Growth Posts 13% Revenue Rise but Stock Still Languishes Under $1
Canopy Growth reported net revenue of $81.2 million CAD, or $58.6 million, in its fiscal 2027 first quarter ended June 30, 2026, a 13% increase over the prior-year quarter, alongside higher gross margins, a 68% decrease in net losses and a 59% drop in adjusted EBITDA losses. Despite the improving results, the cannabis stock remains under $1 per share and has fallen 33% over the past 12 months. Two lingering issues explain the weakness: stalled U.S. legalization progress, after the Department of Justice and Drug Enforcement Administration rescheduled medical marijuana from Schedule I to Schedule III in April 2026 without the broader recreational reforms that would benefit Canopy's U.S. affiliate Canopy USA, and continued dilution, with the share count rising from 239.9 million to 423 million over the past year, largely through at-the-market equity sales in mid-2025. A separate ATM program authorized in August 2025 gives Canopy the right to raise another $200 million, which against a current market cap of $394 million could severely dilute shareholders again.
CGC · Capital · Neutral Q1 revenue rose 13% with higher gross margins and a 68% smaller net loss, but the stock languishes under $1 amid stalled US legalization and heavy dilution from ATM equity sales.
CGC · Regulation · Negative Stalled US legalization after the DOJ/DEA Schedule III rescheduling left out broader recreational reforms that would benefit Canopy USA.
Canopy Growth completes recapitalization, reports medical cannabis revenue growth
Canopy Growth has completed a major recapitalization that significantly reduced its debt burden, ending fiscal 2026 with about $131.3 million in net cash. The company reported 27% fourth-quarter revenue growth in Canadian medical cannabis and 68% growth in international medical cannabis, driven by markets such as Germany. Management has streamlined operations, exited non-core businesses like BioSteel, and completed the acquisition of MTL Cannabis. Despite these improvements, Canopy Growth remains unprofitable and faces intense competition in the Canadian recreational market.
Canopy Growth Unlikely to Benefit From US Marijuana Rescheduling
Canopy Growth is unlikely to see a significant stock boost from the US rescheduling of marijuana, as its core operations remain in Canada and Europe and its US exposure is limited to a non-controlled investment. The company stated in its annual report that it is not a US Marijuana Issuer and has insulated itself from economic and voting interests in Canopy USA, a platform focused on recreational rather than medical use. Rescheduling primarily aims to expand medical access and research, offering little direct benefit to Canopy Growth’s recreational-focused US affiliate. The company recently strengthened its Canadian medical market position by acquiring MTL Cannabis, but its cautious US approach leaves it poorly positioned to capitalize on federal policy changes.
Canopy Growth Q1 revenue rises 13% to C$81.2 million, adjusted EBITDA loss narrows 59%
Canopy Growth reported first-quarter fiscal 2027 net revenue of C$81.2 million, a 13% increase from the prior-year period, with year-over-year growth across its cannabis and Storz & Bickel businesses. Adjusted EBITDA loss narrowed 59% to C$3.2 million, and management reiterated its target of achieving positive adjusted EBITDA during fiscal 2027. Cannabis revenue increased 14%, led by 22% growth in Canadian medical cannabis and 10% growth in both adult-use and international markets. Adjusted consolidated gross margin improved to 31% from 25% a year earlier, while the company is targeting mid-30% margins in the near term and executing against C$8 million of annualized MTL Cannabis synergies. The company expects to begin shipping flower to the United Kingdom imminently, with revenue contributions anticipated in the second half of fiscal 2027.
Canopy Growth Investors Should Wait for DEA Rescheduling Decision Before Buying
Investors considering Canopy Growth may want to wait for the U.S. Drug Enforcement Administration's upcoming decision on rescheduling marijuana to Schedule III before buying shares. The DEA's efforts have been ongoing for months, with recent hearings and an executive order from President Donald Trump calling for reclassification in the most expeditious manner possible, though a final decision date remains unclear. Rescheduling would not resolve all regulatory headwinds but could allow Canopy to move closer to consolidating its U.S. affiliate, Canopy USA, and would benefit Canopy USA by removing deduction limitations under section 280E of the Internal Revenue Code. Past price action suggests that any surge on rescheduling news may be short-lived, as seen in April when cannabis stocks briefly rallied then retreated, making a long-term approach preferable to a short-term bet.
Canopy Growth Stock Still Not a Confident Buy Despite Operational Improvements
Canopy Growth has lost more than 99% of its value since its 2018 peak, but the company is now healthier with fiscal 2026 revenue up 6% to $200.4 million and cannabis revenue climbing 15%. Canadian medical cannabis revenue hit a record, international sales rebounded, and management targets positive adjusted EBITDA in fiscal 2027. The balance sheet improved to a net cash position of $92 million, yet the company remains unprofitable with negative free cash flow and a history of shareholder dilution. Until consistent profitability is demonstrated, the stock is seen as carrying too many execution risks to be a confident buy.
Canopy Growth Stock Could Deliver a 4X Gain, Says Roth Capital Analyst
Roth Capital Partners analyst Bill Kirk reiterated a buy rating and a 5 Canadian dollar price target on Canopy Growth, implying a roughly fourfold gain from current levels. Kirk cited record adjusted EBITDA in the recently completed fiscal fourth quarter when excluding one-time expenses, along with improved market share and cost-reduction efforts. However, his own fiscal 2027 estimates project only modest revenue growth of about 5.1% and near-breakeven adjusted EBITDA, making a 4x surge difficult to envision. The average analyst price target stands at $1.22 per share, about 27% above recent trading levels. Investors bullish on U.S. legalization may find stronger fundamentals in already profitable state-licensed U.S. cannabis companies.
Canadian shares are turning in a mixed performance on Thursday with investors digesting rate cut moves by the Bank of Canada and the European Central Bank, along with the latest economic data. The benchmark S&P/TSX Composite Index was up 41.58 points or 0.2% at 22,186.60 after advancing to 22,234.97. Materials and energy stocks found support, while other sectors were mixed. In economic news, the Ivey Purchasing Managers Index fell to 52 in May from a two-year high of 63, and Canada's trade deficit narrowed to about C$1.05 billion in April as exports surged 2.6% to C$64.5 billion. Among individual movers, Canopy Growth declined 8% after establishing an at-the-market equity program to sell up to $250 million of common shares.
Cannabis rescheduling hearing begins but prediction markets price low odds of 280E relief
The DEA's expedited administrative hearing on moving cannabis from Schedule I to Schedule III began June 29, 2026, with a conclusion targeted for mid-July, a move that would eliminate the Section 280E tax burden that forces U.S. cannabis operators to pay effective tax rates above 70%. The AdvisorShares Pure US Cannabis ETF has rallied 99.2% over the trailing year on rescheduling hopes but remains 81% below its September 2020 launch price. Prediction markets, however, price just an 18.5% probability of rescheduling by the end of July and 23.3% by year-end, with a contract for rescheduling by March 31 having already expired worthless. Canadian licensed producers Tilray Brands and Canopy Growth, which are not subject to 280E, have seen their shares fall 97.5% and 99.6% respectively from their peaks, mirroring the boom-and-bust pattern of prior reform cycles. For U.S. multi-state operators held in the AdvisorShares fund, 280E relief would be a structural unlock, shifting cash flows from the IRS to the income statement and narrowing the capital-raising discount, but timing has repeatedly destroyed capital in the sector.
Canopy Growth's Medical Marijuana Sales Surge 27% in Q4, but Broader Losses Persist
Canopy Growth reported a 27% increase in medical marijuana revenue in the fourth quarter of fiscal 2026, and a 17% rise for the full fiscal year, driven by its recent acquisition of MTL Cannabis. However, the company's recreational cannabis revenue grew only 1% in the fourth quarter, international cannabis sales fell 7% year over year, and its Storz & Bickel vaporizer business declined 14%. Gross margin dropped four percentage points in the quarter and six points for the full year, and Canopy Growth posted negative earnings for the tenth consecutive year since going public. The company also recapitalized its balance sheet by exchanging shares for debt, leaving only the most aggressive investors likely to bet on a sustained rally.
Canada
United States
